Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/115847
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMehr, S.en
dc.contributor.authorAllen, R.en
dc.contributor.authorBoros, C.en
dc.contributor.authorAdib, N.en
dc.contributor.authorKakakios, A.en
dc.contributor.authorTurner, P.en
dc.contributor.authorRogers, M.en
dc.contributor.authorZurynski, Y.en
dc.contributor.authorSingh-Grewal, D.en
dc.date.issued2016en
dc.identifier.citationJournal of Paediatrics and Child Health, 2016; 52(9):889-895en
dc.identifier.issn1034-4810en
dc.identifier.issn1440-1754en
dc.identifier.urihttp://hdl.handle.net/2440/115847-
dc.description.abstractAim: Cryopyrin-associated periodic syndromes (CAPS) encapsulate three auto-inflammatory conditions, ranging in severity from mild (familial cold auto-inflammatory syndrome: FCAS), moderate (Muckle-Wells syndrome: MWS) and severe (neonatal onset multi-inflammatory disorder: NOMID). We aimed to describe the epidemiology, clinical features and outcomes of Australian children and adults with CAPS. Methods: Patients were identified and clinical data collected through a questionnaire sent during 2012-2013 to clinicians reporting to the Australian Paediatric Surveillance Unit and subscribing to the Australasian Societies for Allergy/Immunology, Rheumatology and Dermatology. Results: Eighteen cases of CAPS were identified (8 NOMID; 8 MWS, 2 FCAS); 12 in children <18 years of age. The estimated population prevalence of CAPS was 1 per million persons. Diagnostic delay was frequent, particularly in those with milder phenotypes (median diagnostic delay in MWS/FCAS 20.6 years compared with NOMID 2.1 years; P = 0.04). Common presenting features included urticaria (100%), periodic fever (78%), arthralgia (72%) and sensorineural hearing loss (61%). Almost all (90%) MWS patients had a family member similarly affected compared with none in the NOMID group (P = 0.004). A significant proportion of patients on anti-interleukin (IL)-1 therapy (n = 13) no longer had systemic inflammation. Only 50% with sensorineural hearing loss had hearing restored on anti-IL-1 therapy. Conclusions: Although CAPS are rare, patients often endured prolonged periods of systemic inflammation. This is despite almost all MWS patients having family members with similar symptoms and children with NOMID presenting with chronic infantile urticaria associated with multi-system inflammation. Hearing loss in NOMID/MWS was frequent, and reversible in only 50% of cases.en
dc.description.statementofresponsibilitySam Mehr, Roger Allen, Christina Boros, Navid Adib, Alyson Kakakios, Paul J Turner, Maureen Rogers, Yvonne Zurynski and Davinder Singh-Grewalen
dc.language.isoenen
dc.publisherWileyen
dc.rights© 2016 Paediatrics and Child Health Division (The Royal Australasian College of Physicians)en
dc.subjectCAPS; cryopyrin; epidemiologyen
dc.titleCryopyrin-associated periodic syndrome in Australian children and adults: epidemiological, clinical and treatment characteristicsen
dc.typeJournal articleen
dc.identifier.rmid0030055302en
dc.identifier.doi10.1111/jpc.13270en
dc.identifier.pubid270221-
pubs.library.collectionPaediatrics publicationsen
pubs.library.teamDS14en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
Appears in Collections:Paediatrics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.